Candriam S.C.A. Sells 4,954 Shares of The Clorox Company $CLX

Candriam S.C.A. cut its position in The Clorox Company (NYSE:CLX) by 46.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,627 shares of the company’s stock after selling 4,954 shares during the period. Candriam S.C.A.’s holdings in Clorox were worth $694,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in CLX. Vanguard Group Inc. increased its holdings in shares of Clorox by 1.7% during the second quarter. Vanguard Group Inc. now owns 15,845,496 shares of the company’s stock valued at $1,902,569,000 after acquiring an additional 272,420 shares in the last quarter. Invesco Ltd. grew its position in Clorox by 138.3% in the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock valued at $389,648,000 after purchasing an additional 1,883,465 shares during the period. Norges Bank bought a new stake in Clorox during the 2nd quarter valued at $190,429,000. Arrowstreet Capital Limited Partnership raised its holdings in Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after buying an additional 856,873 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Clorox by 7.0% in the second quarter. ProShare Advisors LLC now owns 1,160,881 shares of the company’s stock valued at $139,387,000 after buying an additional 75,514 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Stock Down 1.1%

Shares of NYSE:CLX opened at $124.62 on Friday. The Clorox Company has a 1 year low of $96.66 and a 1 year high of $159.04. The company has a market capitalization of $15.07 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 0.62 and a beta of 0.59. The business has a fifty day moving average price of $107.21 and a two-hundred day moving average price of $113.74. The company has a debt-to-equity ratio of 71.03, a current ratio of 0.74 and a quick ratio of 0.48.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). Clorox had a return on equity of 383.01% and a net margin of 11.17%.The company had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the firm posted $1.55 earnings per share. Clorox’s quarterly revenue was down .8% compared to the same quarter last year. Analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 annualized dividend and a dividend yield of 4.0%. Clorox’s dividend payout ratio (DPR) is presently 81.05%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Clorox from $114.00 to $112.00 and set a “hold” rating for the company in a research report on Wednesday, February 4th. Morgan Stanley boosted their price objective on Clorox from $125.00 to $136.00 and gave the stock an “equal weight” rating in a report on Thursday, February 5th. Wells Fargo & Company raised their target price on Clorox from $108.00 to $115.00 and gave the company an “equal weight” rating in a report on Friday, January 23rd. BNP Paribas Exane raised Clorox from an “underperform” rating to a “neutral” rating in a research report on Wednesday. Finally, Citigroup increased their price target on Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $117.93.

Insider Activity at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were acquired at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the completion of the purchase, the director owned 13,000 shares in the company, valued at approximately $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.63% of the company’s stock.

Key Headlines Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox paid a $1.24 dividend on Feb. 13, continuing a 48‑year streak of consecutive dividend increases — a strong signal for income investors supporting demand for CLX shares. Clorox’s 5% Yield Dominates Consumer Staples: Can It Continue?
• Positive Sentiment: Coverage pieces highlighting Clorox as a high‑yield, dividend-bearing consumer staple have kept investor interest intact despite near‑term headwinds. Consumer Staples Look Pricey. Consider Clorox and Other High Yielders With Solid Dividends.
• Neutral Sentiment: Q2 was mixed — revenue slightly beat estimates but EPS missed; International and Health & Wellness helped offset weakness in Household and Lifestyle, leaving guidance/forward outlook uncertain. Q2 Deep Dive: Evaluating Clorox’s Financial and Operating Metrics
• Neutral Sentiment: Analysts and commentators are debating valuation after the mixed quarter and ongoing ERP and promotion headwinds — some see buying value after a rebound, others see mixed upside. A Look At Clorox’s Valuation After A Mixed Quarter And Ongoing ERP And Promotion Headwinds
• Neutral Sentiment: Sector context: CLX has outperformed several staples peers year‑to‑date, which supports momentum-oriented buyers even as company‑specific risks persist. P&G Rallies Under New CEO but Lags Rivals, Faces Tariff Challenges
• Negative Sentiment: Margin pressure is a recurring theme — analysts warn a margin squeeze could force changes to Clorox’s capital-return mix (buybacks vs. dividend), which is bearish for total-return expectations. Is Clorox’s (CLX) Margin Squeeze Reshaping Its Capital Return Playbook?
• Negative Sentiment: Barclays reaffirmed a sell rating, keeping downside pressure from investor sentiment and potential selling. Barclays Reaffirms Their Sell Rating on Clorox (CLX)
• Negative Sentiment: RBC Capital left a Hold rating in place, another signal of limited near‑term upside from some institutional investors. RBC Capital Sticks to Its Hold Rating for Clorox (CLX)

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.